NPCE — Neuropace Cashflow Statement
0.000.00%
Last trade - 00:00
- $393.71m
- $384.21m
- $65.42m
- 45
- 11
- 93
- 48
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -30 | -24.3 | -36.1 | -47.1 | -33 |
Depreciation | |||||
Non-Cash Items | 4.52 | 4.42 | 10.8 | 14.7 | 15.6 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.009 | -2.07 | 0.368 | -4.79 | -2.48 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -25 | -21.6 | -24.6 | -36.9 | -19.7 |
Capital Expenditures | -0.468 | -0.062 | -0.384 | -0.603 | -0.173 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 4.09 | -10.7 | -85 | 24.4 | 23.2 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 3.62 | -10.8 | -85.4 | 23.8 | 23 |
Financing Cash Flow Items | 0 | -1.16 | -3.39 | -0.406 | -0.564 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 21.4 | 55 | 103 | 0.49 | 8.13 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -0.038 | 22.6 | -7.45 | -12.6 | 11.5 |